NCT00702260已完成不适用
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was to prove the bioequivalence of Ramipril 10 mg capsules under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Ramipril or any comparable or similar product.
结局指标
主要结局
Bioequivalence
时间窗: Baseline, two-period, 7 day washout
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting ConditionsHypertensionNCT00702091Roxane Laboratories39
已完成
1 期
Ramipril 10 mg Capsule in Healthy Subjects Under Fasting ConditionsHealthyNCT00829452Teva Pharmaceuticals USA40
已完成
1 期
Ramipril 10 mg Capsule in Healthy Subjects Under Fed ConditionsHealthyNCT00829530Teva Pharmaceuticals USA40
已完成
1 期
Ramipril 10 mg Capsule in Healthy Subjects Under Fasting ConditionsHealthyNCT00828321Teva Pharmaceuticals USA40
已完成
1 期
Bioequivalence study of a new capsule containing ramipril 10 mg and bisoprolol fumarate 5 mg (Neopharmed Gentili S.r.l.) versus the simultaneous administration of ramipril 10 mg tablets ( Triatec®, Sanofi-Aventis) and bisoprolol fumarate 5 mg film coated tablets (Congescor®, Daiichi Sankyo) in healthy male and female volunteers under fasting conditionsot applicableISRCTN35244287eopharmed Gentili S.r.l.36